CN108264535A - 一种抗抑郁化合物及其制备方法和应用 - Google Patents

一种抗抑郁化合物及其制备方法和应用 Download PDF

Info

Publication number
CN108264535A
CN108264535A CN201611260514.6A CN201611260514A CN108264535A CN 108264535 A CN108264535 A CN 108264535A CN 201611260514 A CN201611260514 A CN 201611260514A CN 108264535 A CN108264535 A CN 108264535A
Authority
CN
China
Prior art keywords
substitution
alkyl
aryl
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201611260514.6A
Other languages
English (en)
Chinese (zh)
Inventor
黄成钢
李扬
蒋华良
谢阳
郭飞
李志雄
陈明苍
郑明月
孙兆林
高羽
田小亭
胡培
张兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica
Original Assignee
Shanghai Institute of Materia Medica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica filed Critical Shanghai Institute of Materia Medica
Priority to CN201611260514.6A priority Critical patent/CN108264535A/zh
Priority to PCT/CN2017/120134 priority patent/WO2018121770A1/zh
Priority to EP17889516.5A priority patent/EP3564253B1/en
Priority to CN201780081277.3A priority patent/CN110121502B/zh
Priority to JP2019536014A priority patent/JP6901569B2/ja
Priority to US16/474,668 priority patent/US11142543B2/en
Publication of CN108264535A publication Critical patent/CN108264535A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CN201611260514.6A 2016-12-30 2016-12-30 一种抗抑郁化合物及其制备方法和应用 Pending CN108264535A (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN201611260514.6A CN108264535A (zh) 2016-12-30 2016-12-30 一种抗抑郁化合物及其制备方法和应用
PCT/CN2017/120134 WO2018121770A1 (zh) 2016-12-30 2017-12-29 一种抗抑郁化合物及其制备方法和应用
EP17889516.5A EP3564253B1 (en) 2016-12-30 2017-12-29 Antidepressant compound and preparation method and application thereof
CN201780081277.3A CN110121502B (zh) 2016-12-30 2017-12-29 一种抗抑郁化合物及其制备方法和应用
JP2019536014A JP6901569B2 (ja) 2016-12-30 2017-12-29 抗うつ化合物およびその製造方法と使用
US16/474,668 US11142543B2 (en) 2016-12-30 2017-12-29 Antidepressant compound and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611260514.6A CN108264535A (zh) 2016-12-30 2016-12-30 一种抗抑郁化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN108264535A true CN108264535A (zh) 2018-07-10

Family

ID=62707894

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201611260514.6A Pending CN108264535A (zh) 2016-12-30 2016-12-30 一种抗抑郁化合物及其制备方法和应用
CN201780081277.3A Active CN110121502B (zh) 2016-12-30 2017-12-29 一种抗抑郁化合物及其制备方法和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780081277.3A Active CN110121502B (zh) 2016-12-30 2017-12-29 一种抗抑郁化合物及其制备方法和应用

Country Status (5)

Country Link
US (1) US11142543B2 (cg-RX-API-DMAC10.html)
EP (1) EP3564253B1 (cg-RX-API-DMAC10.html)
JP (1) JP6901569B2 (cg-RX-API-DMAC10.html)
CN (2) CN108264535A (cg-RX-API-DMAC10.html)
WO (1) WO2018121770A1 (cg-RX-API-DMAC10.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053854A (zh) * 2018-09-29 2018-12-21 莱芜清博汇能医药科技有限公司 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
CN109206472A (zh) * 2018-09-27 2019-01-15 华东理工大学 薯蓣皂苷元衍生物、其药物组合物及其应用
CN109988218A (zh) * 2017-12-29 2019-07-09 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
CN113831382A (zh) * 2020-06-24 2021-12-24 中国科学院上海药物研究所 一种甾体化合物
CN116621912A (zh) * 2022-02-18 2023-08-22 北京清博汇能医药科技有限公司 基于菝契皂苷元结构的衍生物及其药物组合物的用途
WO2023155757A1 (zh) * 2022-02-18 2023-08-24 北京清博汇能医药科技有限公司 基于菝契皂苷元结构的衍生物及其药物组合物的用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019129176A1 (zh) * 2017-12-29 2019-07-04 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
CN112142817B (zh) * 2019-06-26 2021-10-22 中国科学院上海药物研究所 一种抗抑郁甾体化合物
CN113831381A (zh) * 2020-06-24 2021-12-24 中国科学院上海药物研究所 一种用于治疗抑郁症的甾体化合物
CN113292629B (zh) * 2021-06-21 2022-04-26 西南民族大学 薯蓣皂苷元羟肟酸类衍生物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
PL213697B1 (pl) * 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
WO2005051381A1 (en) * 2003-11-26 2005-06-09 Biovitrum Ab Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R)
WO2005051380A1 (en) 2003-11-26 2005-06-09 Biovitrum Ab Substituted urea-octahydroindols as antagonists of melanin concentrating hormone receptor 1 (mch1r)
US20050245495A1 (en) * 2004-04-07 2005-11-03 Chen Zhao Azacyclosteroid histamine-3 receptor ligands
US7879834B2 (en) 2004-08-19 2011-02-01 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
CN101214253B (zh) 2008-01-07 2011-09-21 中国人民解放军第二军医大学 知母皂苷b-ⅱ用于制备抗抑郁产品的用途
WO2009109477A1 (en) 2008-03-05 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinolines
CN101768202B (zh) 2009-02-18 2013-10-30 沈阳药科大学 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途
CN102924559B (zh) * 2012-11-16 2015-10-28 沈阳药科大学 菝葜皂苷元衍生物及其制备和应用
WO2015163318A1 (ja) * 2014-04-25 2015-10-29 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤
WO2019129176A1 (zh) 2017-12-29 2019-07-04 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109988218A (zh) * 2017-12-29 2019-07-09 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
CN109988218B (zh) * 2017-12-29 2022-11-25 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
CN109206472A (zh) * 2018-09-27 2019-01-15 华东理工大学 薯蓣皂苷元衍生物、其药物组合物及其应用
KR102655595B1 (ko) * 2018-09-29 2024-04-08 피토벤트 바이오파마 지모의 사르사사포게닌 구조를 기반으로 하는 유도체, 약물 조성물 및 그의 용도
WO2020062883A1 (zh) * 2018-09-29 2020-04-02 深圳清博汇能医药科技有限公司 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
CN109053854B (zh) * 2018-09-29 2021-05-14 深圳清博汇能医药科技有限公司 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
KR20210096074A (ko) * 2018-09-29 2021-08-04 피토벤트 바이오파마 지모의 사르사사포게닌 구조를 기반으로 하는 유도체, 약물 조성물 및 그의 용도
CN109053854A (zh) * 2018-09-29 2018-12-21 莱芜清博汇能医药科技有限公司 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
AU2019345516B2 (en) * 2018-09-29 2022-10-20 Phytovent Biopharma Derivative of sarsasapogenin, pharmaceutical composition and use thereof
US12448410B2 (en) 2018-09-29 2025-10-21 Phytovent Biopharma Derivative of sarsasapogenin, pharmaceutical composition and use thereof
CN113831382A (zh) * 2020-06-24 2021-12-24 中国科学院上海药物研究所 一种甾体化合物
WO2023155757A1 (zh) * 2022-02-18 2023-08-24 北京清博汇能医药科技有限公司 基于菝契皂苷元结构的衍生物及其药物组合物的用途
CN116621912A (zh) * 2022-02-18 2023-08-22 北京清博汇能医药科技有限公司 基于菝契皂苷元结构的衍生物及其药物组合物的用途
CN116621912B (zh) * 2022-02-18 2026-07-10 北京清博汇能医药科技有限公司 基于菝契皂苷元结构的衍生物及其药物组合物的用途

Also Published As

Publication number Publication date
WO2018121770A1 (zh) 2018-07-05
CN110121502B (zh) 2022-09-23
JP2020503341A (ja) 2020-01-30
JP6901569B2 (ja) 2021-07-14
EP3564253A1 (en) 2019-11-06
EP3564253A4 (en) 2020-07-29
US20200385418A1 (en) 2020-12-10
US11142543B2 (en) 2021-10-12
CN110121502A (zh) 2019-08-13
EP3564253B1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
EP3564253B1 (en) Antidepressant compound and preparation method and application thereof
US11149006B2 (en) Compounds as neurokinin-1 receptor antagonists and uses thereof
TWI357327B (en) Pyrazoline compounds
ES3014632T3 (en) Cannabinoid derivatives
CN108366996A (zh) 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物
CN103130737B (zh) 环己烷胺类化合物及其作为抗精神分裂症药物的应用
TWI579277B (zh) 取代桂皮醯胺衍生物、其製備方法、其應用及醫藥組成物
JP5701213B2 (ja) 新規なドーパミンd3受容体リガンド、その調製及び使用
JP2012505165A5 (cg-RX-API-DMAC10.html)
TW202340145A (zh) 氘化有機化合物及其用途
CN105777706B (zh) 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
EA019360B1 (ru) Алканолпиперазиновые производные бензотиофена и их применение в качестве антидепрессанта
WO2019129176A1 (zh) 一种菝葜皂苷元衍生物及其制备方法和应用
CN103360342B (zh) 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
CN109988218B (zh) 一种菝葜皂苷元衍生物及其制备方法和应用
CN113272315B (zh) 一类类固醇化合物及其用途
CA3239518A1 (en) Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
CN119504546B (zh) 内酰胺环类化合物及其用途
CN112142817B (zh) 一种抗抑郁甾体化合物
TW200538099A (en) Fused ring NK1 antagonists
CN107586281A (zh) 芳烷杂环类衍生物及其在多靶点抗抑郁症中的应用
KR102906581B1 (ko) 올레아난 신남아미드 유도체 및 이의 제조 방법과 용도
KR102629506B1 (ko) 피페라진-퀴놀린 유도체로서 2-에틸-5-(4-메틸-피페라진-1-일)-1-(나프탈렌-2-설포닐)-2,3-디하이드로-1h-퀴놀린-4-온의 제조방법
TW201026691A (en) Biaryl spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators
CN115785094B (zh) 苄基取代α-咔啉化合物或其药用盐、其药物组合物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180710

WD01 Invention patent application deemed withdrawn after publication